Search clinical trials for: GDC-6036

Total 1922 results

Genentech, Inc.

Completed

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Healthy
Radboud University Medical Center

Completed

Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients

Prostatic Neoplasms | Immunotherapy | Vaccines | Dendritic Cells

Netherlands
Alkermes, Inc.

Completed

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

Opioid-induced Constipation

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

Melanoma

United States
Dong-A ST Co., Ltd.

Completed

Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome (DES)

Dry Eye Syndrome

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Jonsson Comprehensive Cancer Center

Active, not recruiting

Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules

Thyroid

United States
Genentech, Inc.

Completed

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Healthy Volunteers

United States
Genentech, Inc.

Completed

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors

United States, Korea, Republic of, Spain, United Kingdom, Brazil, Israel, New Zealand, Netherlands, Canada, Australia, Switzerland, Belgium, Italy, Norway, Poland, Hungary, Kenya, Russian Federation, Germany
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

Healthy Volunteers

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

Diabetic Neuropathy, Painful
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

Migraine | Headache
Verastem, Inc.

Completed

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
Verastem, Inc.

Completed

A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects

Healthy Subjects
Genentech, Inc.

Terminated

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Brazil, Argentina, Mexico, Chile, United Kingdom
Genentech, Inc.

Terminated

A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies

Solid Cancers
Genentech, Inc.

Completed

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Solid Tumor

United States
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

Solid Cancers

United States
Verastem, Inc.

Terminated

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Malignant Pleural Mesothelioma

United States
Arrien Pharmaceuticals
Worldwide Clinical Trials

Completed

A Phase 1 Study of ARN-6039 (ARN-6039)

Multiple Sclerosis
Verastem, Inc.

Completed

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Non Hematologic Cancers

Japan
Genentech, Inc.

Completed

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

Healthy Volunteers

United States
Genentech, Inc.

Completed

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Healthy Volunteers
Stanford University
National Cancer Institute (NCI); University Hospitals Cleveland Medical Center

Completed

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Recurrent Skin Cancer | Basal Cell Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Malignant Neoplasm

United States
Genentech, Inc.

Completed

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Cancer

United States
Isabel Cristina Olegário da Costa
University of Guadalajara; University of Dublin, Trinity College; Academic Centre...

Unknown

Glass Ionomer Cement Sealant in the Prevention of Post-eruptive Fractures in Molars Affected by MIH (MIHMex)

Molar Incisor Hypomineralization

Mexico
Verastem, Inc.

Terminated

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND)

Malignant Pleural Mesothelioma

United States, Belgium, United Kingdom, Sweden, Italy, Netherlands, France, Japan, Australia, Canada, New Zealand, Norway, Poland, South Africa, Spain
Centrexion Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Pain | Chronic Pain | Nociceptive Pain

United States
Genentech, Inc.

Approved for marketing

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Genentech, Inc.

Completed

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom
Genentech, Inc.

Completed

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Non-Hodgkin's Lymphoma, Solid Cancers

United Kingdom
Genentech, Inc.

Completed

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Tumor

Canada, United States
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Cancers

United States
Genentech, Inc.

Completed

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

Healthy Volunteer

United States
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

Adult Medulloblastoma

United States
National Cancer Institute (NCI)
Genentech, Inc.

Terminated

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease

United States
Genentech, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
University of Oklahoma
VA Office of Research and Development

Terminated

Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

Brain Ischemia | Brain Infarction

United States
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

Rheumatoid Arthritis

United States, Germany, New Zealand
OPKO Health, Inc.
Tel-Aviv Sourasky Medical Center

Completed

A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects

Obesity

Israel
Genentech, Inc.

Terminated

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-versus-host Disease

United States, Canada
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom, France
Genentech, Inc.

Completed

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Endometrial Carcinoma

United States

3

Subscribe